m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent
Affiliation
Department of Internal Medicine, College of Medicine-Phoenix, University of ArizonaIssue Date
2022
Metadata
Show full item recordPublisher
Frontiers Media S.A.Citation
Kong, J., Lu, S., Zhang, L., Yao, Y., Zhang, J., Shen, Z., Luo, M., Liu, B., Zheng, J., & Lin, T. (2022). M6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent. Frontiers in Immunology, 13.Journal
Frontiers in ImmunologyRights
Copyright © 2022 Kong, Lu, Zhang, Yao, Zhang, Shen, Luo, Liu, Zheng and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Purpose: Immune checkpoint blockade agents were shown to provide a survival advantage in urothelial carcinoma, while some patients got minimal benefit or side effects. Therefore, we aimed to investigate the prognostic value of m6A methylation regulators, and developed a nomogram for predicting the response to atezolizumab in urothelial carcinoma patients. Methods: A total of 298 advanced urothelial carcinoma patients with response data in the IMvigor210 cohort were included. Differential expressions of 23 m6A methylation regulators in different treatment outcomes were conducted. Subsequently, a gene signature was developed in the training set using the least absolute shrinkage and selection operator (LASSO) regression. Based on the multivariable logistic regression, a nomogram was constructed by incorporating the gene signature and independent clinicopathological predictors. The performance of the nomogram was assessed by its discrimination, calibration, and clinical utility with internal validation. Results: Six m6A methylation regulators, including IGF2BP1, IGF2BP3, YTHDF2, HNRNPA2B1, FMR1, and FTO, were significantly differentially expressed between the responders and non-responders. These six regulators were also significantly correlated with the treatment outcomes. Based on the LASSO regression analysis, the gene signature consisting of two selected m6A methylation regulators (FMR1 and HNRNPA2B1) was constructed and showed favorable discrimination. The nomogram integrating the gene signature, TMB, and PD-L1 expression on immune cells, showed favorable calibration and discrimination in the training set (AUC 0.768), which was confirmed in the validation set (AUC 0.755). Decision curve analysis confirmed the potential clinical usefulness of the nomogram. Conclusions: This study confirmed the prognostic value of FMR1 and HNRNPA2B1, and constructed a nomogram for individualized prediction of the response to atezolizumab in patients with urothelial carcinoma, which may aid in making treatment strategies. Copyright © 2022 Kong, Lu, Zhang, Yao, Zhang, Shen, Luo, Liu, Zheng and Lin.Note
Open access journalISSN
1664-3224PubMed ID
36189296Version
Final published versionae974a485f413a2113503eed53cd6c53
10.3389/fimmu.2022.1014861
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2022 Kong, Lu, Zhang, Yao, Zhang, Shen, Luo, Liu, Zheng and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
Related articles
- Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
- Authors: Guo W, Tan F, Huai Q, Wang Z, Shao F, Zhang G, Yang Z, Li R, Xue Q, Gao S, He J
- Issue date: 2021
- A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder.
- Authors: Zheng B, Wang J, Zhao G, Chen X, Yao Z, Niu Z, He W
- Issue date: 2021 Apr 30
- Comprehensive Analysis of N6-Methyladenosine RNA Methylation Regulators in the Diagnosis and Subtype Classification of Acute Myocardial Infarction.
- Authors: Wang X, Wu Y, Guo R, Zhao L, Yan J, Gao C
- Issue date: 2022
- Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
- Authors: Chen S, Zhang N, Wang T, Zhang E, Wang X, Zheng J
- Issue date: 2020
- N6-methyladenosine regulators are potential prognostic biomarkers for multiple myeloma.
- Authors: Wang J, Zuo Y, Lv C, Zhou M, Wan Y
- Issue date: 2023 Feb

